LCM
MAIA icon

Lynwood Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Lynwood Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,000
Closed -$77K – 99
2023
Q2 		$77K Buy
+35,000
New +$93.6K 0.1% 78
2023
Q1 		– Sell
-250,000
Closed -$878K – 136
2022
Q4 		$878K Buy
250,000
+50,215
+25% +$174K 1.06% 37
2022
Q3 		$659K Buy
+199,785
New +$845K 0.72% 50

Other funds holding MAIA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lynwood Capital Management's MAIA Position: Q3 2023 in Review

Lynwood Capital Management sold out of MAIA Biotechnology (MAIA) in Q3 2023, closing a stake of 35,000 shares — an estimated $77K sold.

Lynwood Capital Management first reported a position in MAIA in Q3 2022 and held it in 3 quarters. The position peaked at $878K in Q4 2022. 14 funds tracked by Wall St. Rank hold MAIA as of Q3 2023.

  • Lynwood Capital Management reported no remaining MAIA Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 35,000 MAIA Biotechnology shares in Q3 2023, an estimated $77K.
  • Lynwood Capital Management first reported a position in MAIA Biotechnology in Q3 2022 and held it in 3 quarters.
  • Lynwood Capital Management's MAIA Biotechnology position peaked at $878K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q3 2023.

Based on Lynwood Capital Management's 13F filing for Q3 2023, filed 1 Nov 2023.